Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with CIT.

advanced lung cancer
docetaxel
cancer chemotherapy
advanced non-squamous non-small cell lung cancer
non-squamous non-small cell lung cancer
  • 199 views
  • 05 Mar, 2021
  • 142 locations
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in NSCLC

This is a double-blind Phase 3 clinical trial evaluating the efficacy and safety of TRS003 and paclitaxel-carboplatin versus China-approved bevacizumab and paclitaxel-carboplatin in patients with unresectable, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC). Approximately 608 patients will be enrolled in this study from America, Europe, and Asia. …

  • 0 views
  • 25 Jan, 2021
  • 10 locations
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

The study for innovative strategies is warranted in the treatment of advanced non-squamous NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the outcomes

  • 0 views
  • 23 Jan, 2021
  • 2 locations
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage B-IV Non-squamous non-small-cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety …

  • 12 views
  • 21 Jan, 2021
A Trial to Compare the Efficacy Safety Pharmacokinetics and Immunogenecity of HD204 to Avastin in Advanced Non-squamous Non-small Cell Lung Cancer Patients

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin in terms of efficacy, safety, pharmacokinetics and immunogenecity.

bevacizumab
non-squamous non-small cell lung cancer
measurable disease
carboplatin
lung cancer
  • 80 views
  • 24 Jan, 2021
  • 23 locations
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with pemetrexed+cisplatin/carboplatin in subjects with previously untreated metastatic non-squamous NSCLC. The main hypothesis of the study is that BCD-100 in combination with chemotherapy prolongs OS …

  • 0 views
  • 25 Jan, 2021
  • 36 locations
  • 0 views
  • 01 Apr, 2021
  • 54 locations
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.

  • 0 views
  • 26 Jan, 2021
  • 13 locations
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib

  • 0 views
  • 24 Jan, 2021
  • 1 location
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

combined with docetaxel to treat wild-type advanced non-squamous non small cell lung cancer to further improve the patient's PFS or OS.

  • 0 views
  • 26 Jan, 2021
  • 1 location